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Abstract 
Type 2 diabetes (T2D) carries risks of both cardiovascular (CV) (myocardial infarction, 
stroke, peripheral vascular disease) and microvascular (retinopathy/ nephropathy/ neuropathy) 
complications.  Glucose-lowering is an effective strategy for preventing microvascular 
complications, but the extent to which it can reduce CV complications is less certain.  
Glucagon-like peptide-1 (GLP-1) agonists are potent glucose-lowering agents but also have 
potentially beneficial effects on other traditional (body weight, BP, LDL cholesterol) and 
non-traditional risk factors (low grade inflammation, endothelial dysfunction).  The results of 
four large CV outcome trials (CVOTs) with GLP-1 agonists are now available.  These have 
compared lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), and 
long-acting exenatide (EXSCEL) with placebo and standard of care over 2-4 years; four 
others (including with dulaglutide and albiglutide) are ongoing.  LEADER and SUSTAIN-6 
have demonstrated reductions in rates of major adverse CV events (MACE) with active GLP-
1 treatment but ELIXA and EXCSEL have not.  In this review we discuss the mechanisms by 
which GLP-1 receptor agonists act on the CV system and the design and conduct of these 
trials.  Contrary to the assertions that (a) all GLP-1 agonists reduce CV disease in T2D but to 
different extents, or (b) the magnitude of CV protection is predominantly related to glucose-
lowering, we argue that CV benefit is specific to agents that provide longer acting agonism at 
the GLP-1 receptor.  The mechanisms involve reduction in body weight and BP, and lowering 
of LDL-cholesterol and glucose, but pleiotropic effects – including suppression of low grade 
inflammation, vasodilation and natriuresis - are also likely relevant.  
(250 words) 
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Abbreviations  
BP    blood pressure 
CV   Cardiovascular 
CVOT    Cardiovascular Outcome Trial 
ELIXA  The Evaluation of Lixisenatide in Acute Coronary Syndrome 
GLP-1   Glucagon Like Peptide 1 
HR    Hazard ratio 
LEADER The Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results  
MACE Major Adverse Cardiovascular Events 
SUSTAIN-6 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 
Diabetes 
EXSCEL  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 
2 Diabetes  
REWIND Researching Cardiovascular Events With a Weekly Incretin in Diabetes  
T2D Type 2 Diabetes 
Introduction 
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People with Type 2 Diabetes Mellitus (T2D) have a much higher risk of premature CV (CV) 
disease compared with those without T2D and a poorer prognosis following an adverse CV 
event [1,2].  Contemporary data indicate that life expectancy is still reduced by 3-4 years and 
that CV disease is responsible for more than 80% of deaths in those aged 65 years and older 
[3,4]. The importance of the management of BP and other vascular risk factors in T2D has 
been recognised for over two decades, particularly since the publication of the UK 
Prospective Diabetes Study (UKPDS) in 1998 [5,6].  In the USA and other developed 
countries, CV morbidity attributable to T2D is falling, but is offset by a doubling in incidence 
and a tripling in prevalence of the condition (driven in part by greater longevity) [7].  
Advances in the management of risk factors (dyslipidaemia and BP) and clinical care (acute 
metabolic care, revascularisation) have resulted in considerable success in reducing 
cardiovascular and other complications associated with T2D [7].   The impact of a glucose-
lowering strategy using traditional agents (sulphonylureas, insulin) has been less clear [8,9].  
However, more recently, the response of international regulatory systems to a meta-analysis 
suggesting adverse CV effects of the thiazolidinedione rosiglitazone [10] was a catalyst for 
change. Over the last eight years, pharmaceutical companies have been required to conduct 
large double-blind randomised placebo-controlled CV outcome trials (CVOTs) assessing the 
effects of newer agents, including glucagon-like peptide-1 (GLP-1) receptor agonists, on rates 
of Major Adverse Cardiovascular events (MACE) [defined as time to either CV death, non-
fatal myocardial infarction or non-fatal stroke][11].  
Glucose lowering with GLP-1 receptor agonists is associated with weight loss, systolic BP 
reduction, favourable changes in lipid profile and a low risk of hypoglycaemia [11]. Such 
properties make CV benefit with GLP-1 receptor agonists biologically plausible. Six GLP-1 
receptor agonists for subcutaneous injection have been approved for the treatment of T2D 
(exenatide, liraglutide, lixisenatide, dulaglutide, albiglutide, and semaglutide) although the 
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number available fell to five in July 2018 when albiglutide was withdrawn by its 
manufacturer for commercial reasons [12].  A further agent, taspoglutide was halted in 
development in 2010 due to injection-site reactions [13]. 
The original formulation of (twice daily) exenatide became available in 2008 before the 
introduction of the requirement to conduct CVOTs.  Four large CV outcomes trials (CVOTs), 
including a total of 33,457 participants, have now evaluated the efficacy and safety of other 
GLP-1 receptor agonists to date: The Evaluation of Lixisenatide in Acute Coronary 
Syndrome (ELIXA) [14], The Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) [15], Semaglutide and Cardiovascular Outcomes 
in Patients with Type 2 Diabetes (SUSTAIN-6) [16] and Effects of Once-Weekly Exenatide on 
Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) [17]. All have demonstrated safety 
(“non-inferiority”) of the GLP-1 agonist under investigation with respect to placebo and 
standard of care (hereinafter referred to as “placebo”). However, two have also revealed 
reduction in rates of CV events (“superiority”): LEADER and SUSTAIN-6; the reasons for 
differences in results between these CVOTs are discussed below. 
A further four GLP-1 CVOTs await publication: 
(1) FREEDOM-CVO: ITCA 650 is a 3-6 monthly implant that delivers subcutaneous 
exenatide continuously with favourable metabolic effects [18]. In May 2016 a press statement 
was released declaring that the FREEDOM-CVO trial (NCT01455896) in more than 4000 
participants with T2D had met its primary safety endpoint by demonstrating non-inferiority 
for CV safety [19].  However, this has not yet been followed by a full publication. 
(2) PIONEER-6: This is a CVOT with oral semaglutide (NCT02692716) that randomized 
3176 participants with T2D and is due to complete follow-up later in 2018.  Like SUSTAIN-6 
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- which studied the injectable form of the drug – it was designed to confirm safety (non-
inferiority) in comparison with placebo for its primary MACE outcome [20].  
(3) REWIND: The forthcoming Researching Cardiovascular Events With a Weekly Incretin 
in Diabetes (NCT01394952) trial with dulaglutide is due to report later in 2018 [21] and is 
discussed in more detail below.   
(4) HARMONY-Outcomes: Although albiglutide was withdrawn from the market in July 
2018, the HARMONY CVOT (NCT02465515) which randomized 9575 participants to 
albiglutide or placebo was continued to completion and is due to report its findings in 
Autumn 2018 [22].  It was designed to confirm safety (non-inferiority, primary outcome) and 
superiority (secondary outcome) in comparison with placebo for its primary MACE outcome. 
Mechanisms by which GLP-1 agonists may impact CV outcomes are depicted in Figure 1.  
  It has been suggested that all GLP-1 agonists reduce CV disease in T2D but to different 
extents [23], or alternatively that the magnitude of CV protection they provide is 
predominantly related to glucose-lowering [24, 25].  In this review, we attempt to understand 
the differences in the outcomes of the trials to date in the context of their design and conduct 
as well as the pharmacological properties of the individual agents assessed. 
 
 
 
Key trial characteristics  
Key characteristics of each of the four CV outcome trials published to date are shown in 
Table 1.  
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1) ELIXA randomized 6068 participants with T2D at high risk of CV disease, all within 180 
days of an acute coronary event (i.e. a secondary care population), to lixisenatide up to 20 
mcg once daily or placebo [14].  The primary endpoint was an expanded MACE outcome (i.e. 
time to hospitalization for unstable angina in addition to the standard three MACE 
components listed above).  The trial was designed to test initially for non-inferiority vs 
placebo, and subsequently to test for superiority.  It was event-driven with a final median 
follow-up of 2.1 years. 
2) LEADER randomised 9340 participants with T2D to liraglutide up to 1·8 mg once daily or 
placebo [15]. They were either aged ≥ 50 years with “prior CVD” [defined as concomitant 
CVD, cerebrovascular disease, peripheral vascular disease, chronic heart failure (NYHA class 
II or III), chronic kidney disease (stage 3 or higher)] or ≥ 60 years with “no prior CVD” and 
at least one CV risk factor.  The power calculation anticipated 660 primary MACE events but 
the final number was 1302 due to: (i) a higher proportion of participants being recruited into 
the “prior CVD” group than anticipated (81%); (ii) a minimum follow-up period per 
participant of 3.5 years being pre-specified per protocol; and (iii) continuation of the trial as 
planned under the auspices of the Data and Safety Monitoring Board.  This provided much 
greater statistical power than originally anticipated.  Final median follow up was 3.8 years.  
3) SUSTAIN 6 [16] was similar in many respects to LEADER, including entry criteria, but 
smaller as it was designed to demonstrate safety (non-inferiority) of semaglutide over placebo 
rather than superiority, which was not pre-specified. 3297 people with T2D were randomized 
to semaglutide (0·5 mg or 1·0 mg once per week) or placebo with a power calculation based 
on 122 primary MACE events occurring during follow-up.  Final median follow up was 2.1 
years.  
4) EXSCEL was the largest GLP-1 CVOT to date [17].  It compared extended-release 
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exenatide with placebo in 14,752 patients with T2DM aged ≥60 years; 73% (vs. an intended 
70%) had prior CVD.  The design specified an initial assessment of the primary outcome for 
non-inferiority followed by a hierarchical test for superiority. The trial was stopped as 
planned after a median of 3.2 years when 1744 participants had experienced a confirmed 
primary outcome.  
 
Risk factor reduction 
In all four CVOTs, as the main comparison was between GLP-1 agonist and placebo, the 
intention was to treat all participants randomised (including those taking placebo injections), 
actively to target with lifestyle advice, non-incretin glucose-lowering agents (including 
insulin), BP-lowering drugs and statins throughout the trial period.  If this aim had been 
realised, there would therefore have been no differences between the active and placebo 
groups in terms of HbA1c, body weight, or BP as site staff were blinded to treatment 
allocation.  However, because of the powerful glucose-lowering effects and weight-reducing 
properties of GLP-1 agonists in the active group, and the weight gain-inducing properties of 
other agents (particularly sulphonylureas and insulin) used to try and achieve targets in the 
comparator group, differences in risk factors between the randomised groups occurred in all 
four trials.  
Summary data for these differences in risk factor control during follow up for the individual 
trials are given in Table 1. It can be seen that differences between groups were most marked 
for HbA1c and body weight in SUSTAIN-6 with semaglutide, but these were also seen in 
LEADER with liragutide and with long-acting exenatide in EXSCEL. These largely reflect 
the differential efficacy of these individual agents at their marketed doses. 
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Main results (CV outcomes) 
In ELIXA, the primary expanded MACE outcome occurred in 406 patients (13.4%) with 
lixisenatide compared with 399 (13.2%) with placebo [HR 1.02 (95% CI 0.89–1.17)] i.e. non-
inferiority (p < 0.001) was demonstrated with no indication of superiority (p = 0.81) [14]. In 
contrast, in LEADER the primary composite outcome (myocardial infarction, stroke, or CV 
death) occurred less frequently with liraglutide (13.0%) when compared with the placebo 
(14.9%) [HR 0.87 (95% CI 0.78–0.97)] demonstrating not only non-inferiority (p < 0.001) 
but also superiority (p = 0.01) [15]. Deaths from CV causes were also reduced (4.7% with 
liraglutide vs 6.0% with placebo) [HR 0.78 (95% CI 0.66–0.93) as was all cause mortality. 
The number need to treat to prevent a MACE event was 53 over 3.8 years.  In SUSTAIN-6 
the primary MACE outcome occurred in 108 patients (6.6%) on semaglutide compared with 
146 patients (8.9%) on placebo [HR 0.74 (95% CI 0.58–0.95); p < 0.001] [16]. The number 
needed to treat to prevent one CV death, non-fatal MI or non-fatal stroke was 45 for 2 years. 
In EXSCEL [17], the primary MACE end point occurred in 839 patients (11.4%) in the 
extended release exenatide group and in 905 patients (12.2%) in the group receiving placebo 
[HR 0.91 (95% CI 0.83–1.00); p<0.001] confirming non-inferiority.  The test for superiority 
for MACE indicated only a strong trend (p = 0.06) although a significant reduction in all-
cause mortality was noted [HR 0.86 (95% CI 0.77–0.97); p=0.016)].  
 
Other results (microvascular outcomes) 
(i) Nephropathy: In LEADER, the rate of the pre-specified renal secondary composite 
outcome (new-onset macroalbuminuria, doubling of serum creatinine, end-stage renal 
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disease, or death due to renal disease) was reduced with liraglutide vs placebo [15% vs 19%; 
HR 0.78 (95% CI  0.67 to 0.92); p=0.0003).   This was driven by progression to new-onset 
macroalbuminuria [9.0% versus 12.1%; HR 0.74 (95% CI 0.60 to 0.91); p=0.004] [26].  In 
SUSTAIN-6, the rate of a similar renal composite outcome (also pre-specified as a secondary 
endpoint) was also reduced over a shorter time course by semaglutide vs placebo: [3.8% 
versus 6.1%; HR 0.64 (95% CI 0.46-0.88); p=0.005] [16].  In ELIXA, the investigators did 
not consider a modest difference in a pre-specified comparison of percentage change of 
urinary albumin-to-creatinine ratio from baseline between groups (lixisenatide 24% vs. 
placebo 34%, p = 0.004) to be clinically significant as there was little change in absolute 
values and the difference was attenuated after adjustment for HbA1c (p=0.07) [14].  In 
EXSCEL, no renal outcomes were pre-specified but the rate of new-onset macroalbuminuria 
was lower with exenatide than with placebo (2.2% vs 2.8%) [17]; this difference is nominally 
statistically significant if compared without correction for multiple testing.  
(ii) Retinopathy:  Retinal outcomes were pre-specified in LEADER and SUSTAIN-6, but 
not in the other trials [15,16].  These were collected on the basis of local screening methods in 
place at study sites, rather than systematic analysis of retinal photographs, before adjudication 
by a dedicated committee masked to treatment allocation.  In LEADER, the rate of a pre-
specified composite retinal outcome (requirement for photocoagulation, requirement for 
treatment with intravitreal agents, vitreous haemorrhage, or new-onset blindness) was 
numerically slightly higher with liraglutide than placebo [2.3% versus 2.0% events per 100 
patient-years; HR 1.15 (95% CI, 0.87 to 1.52); p = 0.33]. In SUSTAIN-6 the rate of an 
identical composite retinal outcome (pre-specified as a secondary endpoint) was significantly 
higher with semaglutide vs placebo [3.0% versus 1.8%; HR 1.76 (95% CI 1.11 to 2.78); p = 
0.02] [27].  Notwithstanding the limitations of the data, and the potential concerns they raise, 
onset of the effect soon after randomisation has been interpreted (including by international 
 11 
regulatory bodies) as secondary to an initial, rapid improvement in glycaemic control [28].  
An early worsening of retinopathy in response to glucose-lowering was first described in type 
1 diabetes in the Diabetes Control and Complications Trial and subsequently in the Diabetes 
in Early Pregnancy study [29, 30], but was infrequently seen in type 2 diabetes prior to the 
advent of GLP-1 agonists. In ELIXA, retinal outcomes reported as adverse events were 
similar between groups [14]. In EXSCEL, these were pre-specified as adverse events of 
clinical interest: observed rates were similar between groups (2.9% with exenatide vs 3.2% 
with placebo) [17].   
(iii) Composite microvascular outcomes:  In LEADER, development of a pre-specified 
composite outcome consisting of the individual components of the above retinopathy and 
nephropathy outcomes was less likely with liraglutide than with placebo [HR 0.84 (95% CI, 
0.73 to 0.97); p=0.02] [15].  As with the renal composite outcome, this was driven by reduced 
onset of new-onset macroalbuminuria.  Composite microvascular outcomes were not pre-
specified in any of the other GLP-1 CVOTs. 
Why were CV events reduced in some trials but not others?: 
Thus, while lixisenatide, liraglutide, semaglutide and exenatide are all agonists at the GLP-1 
receptor, and their respective CVOTs all met boundaries of regulatory safety, only liraglutide 
and semaglutide reduced rates of CV outcomes i.e. were superior to placebo and standard of 
care.  A number of possible explanations for these apparent differences can be considered.      
(i) Differences in molecular structure: Exenatide is a synthetic form of the peptide exendin-
4, a 39 amino acid peptide originally isolated from the salivary secretions of the Gila monster: 
a single alanine to glycine substitution conferring resistance to degradation by dipeptidyl-
peptidase-4.  The long-acting (once weekly) form used in the EXSCEL trial is the same 
molecule encapsulated in biodegradable polymer microspheres.  Lixisenatide shares 38 amino 
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acids with exendin-4 plus an additional six lysine residues.  These GLP-1 agonists have only 
53% and 50% sequence homology respectively with native human GLP-1.  In contrast, 
liraglutide and semaglutide as synthetic analogues of native GLP-1 have respectively 97% 
and 94% sequence homology.  As native GLP-1 has a half-life of less than five minutes, a 
half-life suitable for therapeutic use is conferred by the addition of a C16 palmitic acid chain 
(liraglutide) or a C18 fatty di-acid side chain (semaglutide) to promote albumin binding, and a 
single (position 34, liraglutide) or dual (positions 8 and 34, semaglutide) amino acid 
substitution [31,32].   
(ii) Differences in duration of action: The GLP-1 receptor agonists vary widely in half-life: 
twice daily exenatide 2.4 hours; lixisenatide 2.7-4.3 hours; liraglutide 11-15 hours; 
dulaglutide 5 days; and semaglutide 1 week; it is more difficult to define a pharmacokinetic 
half-life for long-acting exenatide but it reaches a pharmacodynamic steady state at 6-7 
weeks.  It is notable that those agents for which CV superiority has been demonstrated in 
CVOTs to date are those with longer half-lives and/or duration of action.  This property 
allows them to be administered in a more effective dose range as lower peak-to-trough ratios 
at steady state are associated with less nausea, the main adverse effect of the class (thought to 
be due to acute impairment of gastric emptying).  GLP-1 receptors are not widely found in the 
CV system (except in the sino-atrial node) [33].  However, agonism at the GLP-1 receptor 
may reduce the progression of atherosclerosis indirectly via anti-inflammatory effects, which 
may be associated with a longer duration of action [34, 35].  
 
(iii) Differences in study population: The four CVOTs published to date have studied 
populations at different baseline CV risk: in ELIXA, all participants had experienced a prior 
CV event, in contrast with only 73% of those in EXSCEL.   From a statistical perspective, a 
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higher risk population predicts a higher rate of events and therefore a smaller sample size 
should be required to detect a given effect size (c.f. n = 9340 in LEADER vs n = 14,752 in 
EXSCEL).  However, from a biological perspective, a high risk population may have disease 
that is too advanced to be susceptible to therapy: thus, despite the short duration of action of 
lixisenatide, it is at least in theory possible that it might have reduced rates of CV events if it 
had been studied in a larger, lower risk population, over a longer period of follow-up. 
(iv) Differences in HbA1c between groups: As discussed above, despite “treat to target” 
designs incorporating standard of care in both active and placebo arms, there were differences 
in HbA1c (and other risk factors) between groups in all four of the CVOTs (Table 1).  It has 
been suggested that glycaemic exposure between study arms [36-39] is closely associated 
with CV outcome in these trials [24,25]: while this may not have been the main driver of 
differences in results among the trials, it may have played a role.  For HbA1c, the difference 
was largest in SUSTAIN-6 in which semaglutide was associated with a 0.7% mean difference 
(7.7 mmol/mol) for the 0.5mg dose and a 1.0% mean difference (10.9 mmol/mol) for the 1 
mg dose.  The difference between arms was almost as marked three months after 
randomisation in LEADER with liraglutide at 1.0% (10.9 mmol/mol), but diminished during 
the trial to 0.4% as participants were treated to target with other agents over a longer follow 
up (4.4 mmol/mol).  The difference in HbA1c between randomised groups was smaller in 
both ELIXA with lixisenatide (0.27%, 3.0 mmol/mol) and EXSCEL with exenatide (0.53%, 
5.8 mmol/mol).  This may in part have related to lower efficacy of these agents in the doses 
selected, and/or lower HbA1c concentrations at baseline: no upper boundary for HbA1c was 
specified in the inclusion criteria for LEADER or SUSTAIN-6.  
 (v) Differences in rates of hypoglycaemia between groups: Hypoglycaemia, particularly 
severe hypoglycaemia, is associated with adverse CV outcomes [40].  As addition of 
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traditional glucose-lowering medications with a propensity to cause hypoglycaemia 
(sulphonylureas and insulin) was permitted by protocol in both arms of all four CVOTs, some 
have suggested that larger reductions in rates of CV events in some trials could be attributed 
to higher rates of use of these concomitant medication with consequent excess hypoglycaemia 
in the comparator groups.   However, although LEADER was the only trial to demonstrate a 
significant reduction in rates of severe hypoglycaemia (and rates of CV events) in the active 
GLP-1 agonist arm vs placebo, there was also a strong numerical trend towards a reduction in 
ELIXA (in which there was no reduction in CV event rates).  Moreover, there was no 
significant difference in rates of hypoglycaemia between active and placebo arms in either 
SUSTAIN-6 or EXSCEL and in the former there was a marked reduction in CV event rates 
with semaglutide.  Finally, in a sensitivity analysis in which participants experiencing severe 
hypoglycaemia were excluded, the primary outcome of LEADER was robust [41].  There is 
therefore little evidence to support differential rates of hypoglycaemia as a key predictor of 
the CV outcome results of these trials. 
(vi) Differences in weight and other CV risk factors between groups: Although small 
mean reductions in body weight occurred in comparison to placebo with lixisenatide (-0.7 kg) 
in ELIXA and exenatide (-1.27 kg) in EXSCEL, much larger reductions were observed with 
liraglutide (‒2.3 kg) in LEADER and semaglutide [-2.9 kg with 0.5 mg, -4.4kg with 1.0 mg) 
in SUSTAIN-6.  Similarly, systolic BP was reduced by lixisenatide (0.8 mmHg) in ELIXA 
but - perhaps in part due to higher baseline levels (Table 1) - greater reductions were 
observed with liraglutide in LEADER (1.2mmHg), semaglutide in SUSTAIN-6 [1.3 mmHg 
with 0.5 mg and 2.6 mmHg with 1.0 mg), and exenatide in EXSCEL (1.6 mmHg).  Thus, 
significant reductions in CV events occurred consistently with those treatments that induced 
the largest reductions in body weight and BP. While differences in risk factor control between 
trial arms were not intended in the design of these CVOTs, their occurrence is clinically 
 15 
relevant, as they reflect the real-life pharmacological profile of each agent in doses used in 
the clinic.   
(vii) Other differences in trial design: It has been suggested that a minimum duration of 
follow-up is required for a reduction in CV risk to be detected.  Median duration of follow-up 
varied between the CVOTs from 2.1 years for ELIXA and SUSTAIN-6 to 3.8 and 3.2 years 
in LEADER and EXSCEL. That semaglutide was associated with a reduction in rates of CV 
events in SUSTAIN-6 goes against this suggestion; however, it could still be argued that 
longer duration of follow-up increases the chance of detecting a biological effect: for 
example, this might have allowed the trend observed towards reduction of CV disease with 
exenatide in EXSCEL to reach formal statistical significance. 
 (viii) A class effect?: It has been argued that the effect of GLP-1 receptor agonists to reduce 
rates of CV events can be seen across the class.  In a recent meta-analysis by the EXSCEL 
study group of all four GLP-1 CVOTs published to date, treatment with a GLP-1 receptor 
agonist led to a 10% overall relative risk reduction versus placebo in three-point MACE [HR 
0·90 [95% CI 0·82–0·99); p=0·033], as well as reductions in both CV and all-cause mortality 
[23].  While the result of the EXSCEL trial itself is certainly consistent with this position, 
there was considerable heterogeneity in the MACE component of this meta-analysis (I2 = 
50%), apparently driven by the ELIXA trial. In our view it is difficult to substantiate a claim 
that any “class effect” of GLP-1 agonists in relation to CV outcomes extends to lixisenatide.  
In contrast, those agents that act on the GLP-1 receptor for most (or all) of the 24 hour period 
are associated with reductions (or strong trends towards reductions) in rates of CV events.  As 
some of these effects may be mediated by reductions in body weight, BP, cholesterol and 
HbA1c, the extent to which there are differences in the control of traditional risk factors 
between the active and placebo arms of the four CVOTs may explain, at least in part, the 
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observed differences in outcomes.  However, these do not appear to account for all of the 
variability.  It is likely therefore that there are direct and beneficial actions of GLP-1 agonists 
on the CV system that may include suppression of low grade inflammation, vasodilation, 
natriuresis [34] - and possibly other as-yet-unknown anti-atherosclerotic mechanisms. 
 
Forward to REWIND (and HARMONY Outcomes): 
As discussed above, whether a GLP-1 receptor agonist can be demonstrated to reduce rates of 
CV events in a large outcome trial may depend on:  
a) Trial design: sufficient statistical power (determined by the sample size and accuracy of the 
predicted event rate); adequate duration of follow-up.  
b) Pharmacological profile of the agent: long duration of action; adequate dosing (cf. 
tolerability). 
c) Trial conduct: reduction of traditional CV risk factors; greater reduction of HbA1c in the 
active vs placebo arm.   
At the time of writing, the REWIND trial (see Table 2) comparing dulaglutide 1.5mg per 
week with placebo in 9901 people with T2D has completed recruitment, baseline data have 
been published [21] and results are awaited.  It is of similar size to LEADER but includes a 
lower risk population.  Whereas in LEADER the “no prior CV disease” group over 60 years 
of age were required to have strong CV risk factors such as microalbuminuria, left ventricular 
hypertrophy or impaired LV function, in REWIND the required risk factors include weaker 
risk markers such as concomitant medication with ACE inhibitors or statins.  Due to this 
lower risk (and hence more generalizable) population, a much longer duration of follow-up 
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was planned (up to 8 years per participant) giving 90% power to detect a reduction in MACE 
of 18% i.e. somewhere between the reductions of 13% and 26% detected in LEADER and 
SUSTAIN-6.  Despite these considerations, the power calculation was based on a predicted 
event rate slightly higher than the 1.8% (under)estimate used in designing LEADER and 
SUSTAIN-6 (see Table 1).  Observed event rates will therefore need to be higher than 
predicted to detect an effect size similar to that detected in LEADER. 
The half-life of dulaglutide (five days) is somewhere between liraglutide and semaglutide, 
indicating adequate duration of action.  However, a recent 40 week head-to-head trial 
(SUSTAIN-7) indicated that the marketed doses of dulaglutide have about half the effect on 
weight of the corresponding doses of semaglutide and only 75% of the glucose-lowering 
efficacy [37].  It might therefore be predicted that smaller differences in HbA1c will be seen 
between the active and placebo arms of REWIND than occurred in LEADER and SUSTAIN, 
and that the weight differential between arms may also be smaller as seen in EXSCEL (see 
Table 1), decreasing the chances that a reduction in CV events can be demonstrated due to 
constraints of the study design. 
The methods and baseline characteristics of the HARMONY-Outcomes CVOT with the 
(shortly-to-be discontinued) once-weekly GLP-1 agonist albiglutide was accepted for 
publication just as this article was submitted [42].  It was designed to test non-inferiority for 
MACE (safety) with a subsequent test for superiority. Only participants with prior CV disease 
were included i.e. a higher risk population than any of the other trials except ELIXA.  It was 
pre-specified that participants would require to be followed up for between three and five 
years to accumulate 611 major CV adverse events.  However, as the (blinded) event rate was 
much higher than anticipated there was a risk that the trial would be stopped without adequate 
exposure to ensure safety.  The protocol was therefore amended to stipulate a median follow-
up of at least 1.5 years.  As weekly albiglutide is less-effective than daily liraglutide in terms 
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of HbA1c lowering over 32 weeks [43], differences in HbA1c between the active and placebo 
arms are likely to be smaller than were seen in LEADER.  For the same reasons as speculated 
above in relation to REWIND, and given a limited time to impact atherosclerosis in 
participants with established CV disease, it might therefore be predicted that the trial has a 
better chance of demonstrating safety (non-inferiority) than it has of demonstrating a 
reduction in CV events (superiority). 
The two other forthcoming trials (FREEDOM-CVO and PIONEER-6) were designed only to 
detect non-inferiority: given other results with GLP-1 agonists discussed above, it is likely 
that both will achieve this predominantly regulatory aim [for FREEDOM-CVO see the 2016 
press release cited above (19)]. 
 
Summary  
The advent of GLP-1 agonists ten years ago transformed the treatment of T2D, and has made 
a major impact on metabolic and CV complications.  The regulatory requirement for large 
CVOTs has accelerated this process and allayed early fears on safety, originally focusing on 
pancreatitis, pancreatic carcinoma and medullary thyroid carcinoma.  Taken together, the 
results of the four large trials published to date indicate that although differences exist 
between the GLP-1 receptor agonists in their structure, potency, and effect on CV risk, 
longer-acting agents given in adequate dose are particularly beneficial for the CV system.  
Their effects are mediated by a combination of body weight and BP reduction, lowering of 
LDL cholesterol and glucose, and other mechanisms including, suppression of low grade 
inflammation, vasodilation, and natriuresis.  Although GLP-1 agonists are still principally 
used as “third line” agents in many countries (in part due to route of administration and 
acquisition cost), it is likely that they will increasingly be used at earlier stages of T2D, 
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facilitated by the emergence of oral formulations and better appreciation of the economic 
value to healthcare systems of reducing long–term complications. 
(4574 words) 
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Legends for Tables 
 
Table 1:  Design, baseline characteristics, main results and differences in risk factors between 
groups in the four GLP-1 agonist CV outcome trials published to date 
 
Table 2:  Design and baseline characteristics (where available) of the ongoing GLP-1 CV 
outcome trials 
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Legend for Figure  
Mechanisms by which GLP-1 agonists may exert beneficial effects on the CV system 
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Table 1 
Acronym ELIXA LEADER SUSTAIN-6 EXSCEL 
Registry NCT01147250 NCT01179048 NCT01720446 NCT01144338 
Intervention Lixisenatide  
 
Liraglutide  
 
Semaglutide  Long-acting 
Exenatide 
  
Route Subcutaneous Subcutaneous Subcutaneous Subcutaneous 
Dose Up to 20 mcg 
daily 
Up to 1.8 mg 
daily 
0.5 mg or 1.0 mg 
weekly 
Up to 2 mg weekly 
Comparator Placebo and 
standard of care 
Placebo and 
standard of care 
Placebo and 
standard of care 
Placebo and 
standard of care 
Conducted 2010-2015 2010-2015 2013-2016 2010-2017 
Randomized (n) 6068 9340 3297 14752 
Mean age (years) 59.9 64.3 64.6 61.0 
Mean BMI (kg/m2) 30.1 32.5 32.8 32.7 
Mean HbA1c at inclusion 
(% units) 
7.7 8.7 8.7 8.1 
Mean duration of 
diabetes (years) 
9.2 12.8 13.9 13.1 
Systolic BP (mmHg) 130 138 136 136 
Treatment (%) 
   Insulin1 
  ACE/ ARB1 
  Statin1 
 
33 
85 
93 
 
45 
81 
73 
 
58 
84 
73 
 
46 
77 
74 
Prior CVD1 (%) 100 81 83 73 
Heart failure (%) 22.5 17. 24 16 
eGFR < 60 
ml/min/1.73m2 (%) 
22 24 28.5 21.3 
Primary outcome MACE expanded2 MACE MACE MACE 
Follow-up (years) 2.1  3.8  2.1  3.2  
Target primary events 
in power calculation 
844 660 122 1360 
Predicted MACE event 
rate (% per year) 
7 1.8 1.8 3.8 
Primary events 
observed 
805 1302 254 1744 
Observed event rate 
(per year) 
6.3% 3.7% 3.7% 3.7% 
Non-inferiority for 
MACE demonstrated?3 
Yes Yes Yes Yes 
Superiority for MACE 
demonstrated?3 
No Yes 
(13% reduction) 
Yes4 
(26% reduction) 
Borderline 
(9% reduction)5 
CV death rate reduced ? No Yes No No 
All cause mortality 
reduced? 
No Yes No Yes 
Difference in HbA1c  
(% units) 
0.27*** 0.4*6 1.0***7 0.53***  
Reduction in rate of 
severe hypoglycaemia  
if any (%) 
Numerically 
fewer 
25* None None 
Mean reduction in 
weight (kg) 
0.7*** 2.3*** 4.3***7 1.27*** 
Mean difference in 
systolic BP (mmHg) 
0.8** 1.3 * 2.6 ***7 1.6** 
Retinopathy reported As adverse 
events 
As secondary 
outcome 
As secondary 
outcome 
As adverse events 
of clinical interest 
 
eGFR -= estimated glomerular filtration rate  
 
1at baseline; 2including unstable angina; 3compared with placebo and standard of care; 4result  could not be used for 
regulatory purposes as the comparison was not pre-specified; 5p=0.06; 6at 36 months; 7only results for 1.0 mg dose are 
shown.  *p<0.05; **p<0.01; ***p<0.001 vs placebo and standard of care 
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Table 2  
Acronym FREEDOM-CVO PIONEER-6 REWIND HARMONY 
Registry NCT01455896 NCT02692716 NCT01394952 NCT02465515 
Intervention Exenatide Semaglutide  Dulaglutide Albiglutide 
Route Implant Oral Subcutaneous Subcutaneous 
Dose 60mcg/day 3-7 mg/day1 1.5mg weekly Up to 50 mg 
Comparator Placebo and 
standard of care 
Placebo and 
standard of care 
Placebo and 
standard of care 
Placebo and 
standard of care 
Conducted 2013-2017 2017-Present 2011 - present 2015 – present 
Randomized (n) 4156 3176 9901 9463 
Age for inclusion/ 
mean age (years) 
Over 40 years Over 50 years 66.2 
 
64.1 
Mean BMI (kg/m2) NK NK 32.3 32.3 
Mean HbA1c at 
inclusion (%) 
NK NK 7.3 8.7 
Mean duration of 
diabetes (years) 
NK NK 10.0 13.8 
Treatment 
  Insulin (%)1 
  ACE/ ARB1 (%) 
  Statin1(%) 
 
NK 
NK 
NK 
 
NK 
NK 
NK 
 
24 
81.4 
66 
 
59.3 
81.6 
84 
Established 
CVD1(%) 
100 NK 31.4 100 
Heart failure (%) NK NK 8.6 20.2 
eGFR < 60 
ml/min/1.73m2 
NK NK 22.2 22.6 
Primary outcome MACE MACE MACE MACE 
Primary events in 
power calculation 
NK NK 1200 611  
Predicted MACE 
event rate (per 
year) 
NK NK 2% 2-3% 
Designed to detect 
non-inferiority? 
Yes Yes Yes Yes 
Designed to detect 
superiority? 
No No Yes Yes 
Expected to report NK NK 2019 2018 
 
1approximate dose range 
 
NK, not known 
 
 
 
 
  
 
